|
 |
| ©2004-2008, Quantum Laboratories,
Inc.. All rights reserved.
|
|
|
|
|
|
|
|
|
Alzheimer's
Dementia
•
Protocol A2581078 A randomized, multi-center, parallel group,
double blind study of the efficacy and safety of atorvastatin
80 mg plus an acethylcholinesterase inhibitor versus an
acetylcholinesterase inhibitor alone in the treatment of
mild to moderate Alzheimer’s disease.
•
Protocol BI 1198.52 A Phase II Double Blind, Randomized,
Dose Ranging, Placebo Controlled Multi-center, Safety and
Efficacy Evaluation of three doses of NS 2330 in Patients
with Mild to Moderate Dementia of the Alzheimer’s Type.
For
more information please call (561) 687-2111
|
|
|
|
|
|
|
Our facility identifies and recruits appropriate patients and
monitors them during the study. If you qualify and consent to
participate, there will be no charge for your study medication
and office visits. Additionally, you are responsible for attendence
to regular scheduled appointments.
|
|
|
|
|
Fact:
During any one-year period, up to 50 million Americans suffer
from clearly diagnosable mental disorder involving a degree
of incapacity that interferes with employment, attendence at
school or daily life.
|
|
|
|
